In the Persistence Australian National IBD Cohort study, the one-year persistence rates of anti-TNF inhibitors were 68.1% for infliximab and 64.2% for adalimumab in patients with luminal CD, as well as 79.7% for infliximab and 75.7% for adalimumab in patients with fistulizing CD. This evidence concerns the gene TNF and inflammatory bowel disease.